Department of Infection, Immunity and Cardiovascular Diseases and the Florey Institute for Host-Pathogen Interactions, University of Sheffield, UK; South Yorkshire Regional Department of Infection & Tropical Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Specialised Cancer Services, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Vaccine. 2021 Aug 9;39(34):4778-4783. doi: 10.1016/j.vaccine.2021.07.022. Epub 2021 Jul 20.
Current international guidelines recommend routinely vaccinating haematopoetic stem cell transplant (HSCT) recipients. Despite significant infection-related mortality following autologous HSCT, routine vaccination programmes (RVP) completion is poor. For recovered HSCT recipients, it is uncertain whether catch-up vaccination remains worthwhile years later. To determine potential susceptibility to vaccine preventable infections, we measured antibody titres in 56 patients, a median of 7 years (range 0-29) following autologous HSCT, who had not completed RVP. We found that almost all participants had inadequate titres against diphtheria (98.2%) and pneumococcal infection (100%), and a significant proportion had inadequate titres against measles (34.5%). Of those subsequently vaccinated according to available guidelines, many mounted adequate serological responses. These data suggest a pragmatic catch-up approach for autologous HSCT recipients who have not completed RVP is advisable, with universal vaccination against some pathogens (e.g. Streptococcus pneumoniae and diphtheria) and serologically-guided approaches for others (e.g. measles and varicella zoster virus).
目前的国际指南建议对造血干细胞移植(HSCT)受者进行常规疫苗接种。尽管自体 HSCT 后与感染相关的死亡率很高,但常规疫苗接种计划(RVP)的完成情况很差。对于已康复的 HSCT 受者,多年后补种疫苗是否仍然有价值尚不确定。为了确定对疫苗可预防感染的潜在易感性,我们在自体 HSCT 后中位数为 7 年(范围为 0-29 年)的 56 名未完成 RVP 的患者中测量了抗体滴度。我们发现,几乎所有参与者对白喉(98.2%)和肺炎球菌感染(100%)的抗体滴度不足,并且有相当比例的人对麻疹(34.5%)的抗体滴度不足。根据现有指南随后进行疫苗接种的患者中,许多人产生了足够的血清学反应。这些数据表明,对于未完成 RVP 的自体 HSCT 受者,采取实用的补种方法是明智的,对于某些病原体(例如肺炎链球菌和白喉)进行普遍疫苗接种,并对其他病原体(例如麻疹和风疹病毒)进行血清学指导的方法。